Biochemical markers for CVD risk assessment
US10267809B2 · kind B2 · utility
0Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2016 |
| Grant date | Apr 23, 2019 |
| Priority date | — |
| Expiry date | Jun 6, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided is a method of bioassay for the quantification of N- or C-terminal neo-epitope biomarkers formed by cleavage of a CRP, ApoE, lumican, versican, perlecan, decorin, biglycan or elastin by a proteinase. The method includes contacting a biofluid sample with an antibody reactive with the neo-epitope biomarker and determining the level of binding of the antibody to the biomarker in the sample. The assay is predictive of risk of cardiovascular disease events.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.